+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined disease with pulmonary arterial hypertension and pulmonary venous hypertension revealed after treatment of heart failure with preserved ejection fraction in a case with primary Sjögren syndrome



Combined disease with pulmonary arterial hypertension and pulmonary venous hypertension revealed after treatment of heart failure with preserved ejection fraction in a case with primary Sjögren syndrome



Modern Rheumatology 28(1): 193-196



A 49-year-old woman with primary Sjögren syndrome initially developed pulmonary venous hypertension (PVH) due to heart failure with preserved ejection fraction. Endomyocardial biopsy specimens showed mild myocardial fibrosis. Pulmonary arterial hypertension (PAH) was revealed after the treatment with diuretics. During the treatment for PAH using upfront combination with pulmonary vasodilators and immunosuppressants, the patient developed combined disease with PAH and PVH. A careful hemodynamic assessment is necessary in such cases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057443962

Download citation: RISBibTeXText

PMID: 26052802

DOI: 10.3109/14397595.2015.1059989


Related references

Comparison of Pulmonary Artery (PA) Wave Reflections in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction (PH-HFpEF). Journal of Heart and Lung Transplantation 34(4): S118-S119, 2015

Pulmonary Arterial Reactivity in Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension Similar to Pulmonary Arterial Hypertension. Journal of Cardiac Failure 19(8): S3-S4, 2013

Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 198(5): 681-684, 2018

Capillary pCO2 helps distinguishing idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction. Respiratory Research 16: 34, 2015

Heart Failure with Preserved Ejection Fraction Induced Reactive Pulmonary Hypertension Lacks Nitric Oxide Vasoreactivity Similar to Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation 33(4): S146-S147, 2014

Treatment Of Pulmonary Arterial Hypertension Associated With Heart Failure With Preserved Ejection Fraction: A Pilot Study Of Ranolazine. Chest 144(4): 1022A-1022B, 2013

In situ expression of Bcl-2 in pulmonary artery endothelial cells associates with pulmonary arterial hypertension relative to heart failure with preserved ejection fraction. Pulmonary Circulation 6(4): 551-556, 2016

Differentiating Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension from Pulmonary Hypertension Using Demographic Data and Common Blood Measurements. Journal of Heart and Lung Transplantation 33(4): S147-S148, 2014

Airway bypass stents for emphysema, algorithm to exclude precapillary pulmonary hypertension, and sildenafil for pulmonary hypertension in heart failure with preserved ejection fraction. American Journal of Respiratory and Critical Care Medicine 185(12): 1323-1324, 2012

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Failure Reviews 21(3): 285-297, 2016

Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction. American Journal of Respiratory Cell and Molecular Biology 56(4): 497-505, 2017

Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. Journal of Heart and Lung Transplantation 35(11): 1370-1373, 2016

Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137(17): 1796-1810, 2018

Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction. Circulation. Heart Failure 8(2): 278-285, 2015

Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. International Journal of Cardiology 283: 152-158, 2019